Trial reportFrontiers in immunology2025
Immunomodulatory effects and mechanisms of Qi-Xu-Tiao-Ti formula in Qi-deficiency constitution: a randomized controlled trial integrated with multi-omics and network pharmacology analysis.
Trial report in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association Between Nasopharyngeal Carcinoma and Chinese Medicine Constitution: A Meta-Analysis.Cancer medicine · 2026Pooled it
- The influence of Baduanjin on sleep and depression and anxiety of college students with Qi-deficiency constitution: a randomized controlled trial.Frontiers in sports and active living · 2026Trial
- Metabolic Modulation of Type 2 Diabetes Mellitus by 1-Deoxynojirimycin: A Multifaceted Approach.Antioxidants (Basel, Switzerland) · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Qi-deficiency constitution (QDC) is a body constitution type characterized by weakened immune function and increased susceptibility to infectious diseases. Emerging evidence indicates that Chinese herbal medicine can effectively improve immunological competence in individuals with QDC. This study aims to systematically evaluate the clinical efficacy of the Qi-Xu-Tiao-Ti Formula (QXTTF) in alleviating QDC and elucidate its underlying pharmacological mechanisms through transcriptome sequencing and network pharmacology approaches. Methods: This single-center randomized controlled trial was performed using QXTTF to treat the QDC subjects, with Balanced constitution (BC) as the healthy controls. Primary outcome measures focused on traditional Chinese medicine constitution assessment of QDC scores, with secondary evaluation parameters including immune biomarkers (IgA and IgG levels) and adverse events monitoring. To investigate the molecular mechanisms, we performed transcriptomic profiling to identify QXTTF-responsive gene targets, followed by integrated network pharmacology analysis, molecular docking simulations to characterize the compound-target interactions underlying QXTTF's therapeutic effects, and ultimately validated at the proteomics level. Results: This study recruited 78 participants, comprising 63 QDC and 15 BC individuals. Comparative analysis between QDC and BC groups revealed significant differences in immunoglobulin IgA, IgG levels, and transcriptomic profiles. QXTTF intervention on QDC subjects significantly reduced the QDC scores ( Conclusions: Our study demonstrates that QXTTF potentially mitigates QDC via immunomodulatory mechanisms. with therapeutic targets systematically identified through network pharmacology analysis and subsequently validated by molecular docking and proteomic profiling. These insights are crucial in delineating the pharmacological mechanisms of Chinese herbal formulas that augment the immune function of QDC, thus establishing a scientific basis for the early prevention and management of immune-related diseases. Clinical trial registration: http://www.chictr.org.cn/, identifier ChiCTR2200063044.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.